Buratti Laura, Natanti Alice, Viticchi Giovanna, Falsetti Lorenzo, Lattanzi Simona, Pulcini Alessandra, Petrelli Cristina, Provinciali Leandro, Silvestrini Mauro
Neurological Clinic, Marche Polytechnic University, Ancona, Italy.
Internal and Subintensive Medicine, Ospedali Riuniti Ancona, Italy.
Epilepsy Behav. 2018 Mar;80:21-24. doi: 10.1016/j.yebeh.2017.11.023. Epub 2018 Jan 20.
The aim of this study was to investigate the presence of sleep disturbances in patients with juvenile myoclonic epilepsy (JME) using sleep questionnaires. Further, we tried to evaluate whether alterations in sleep quality may influence the clinical expression of JME.
Sixty-two patients with JME treated with levetiracetam were included. Demographic and clinical variables were collected. Moreover, all patients submitted the Pittsburgh Sleep Quality index (PSQI) and the Epworth Sleepiness Scale (ESS) in order to respectively assess sleep quality during the last month and daytime sleepiness. All patients were followed up for a 6-month period and divided in two groups: seizure-free (Group 1) and seizure recurrence (Group 2). The PSQI and ESS scores were synthesized as binary variables <5/≥5 and <10/≥10, respectively. A comprehensive analysis was performed to evaluate the independent effect of the sleep quality and daytime sleepiness on the risk of having seizures during the follow-up.
Both reduced sleep quality during the last month and daytime sleepiness were associated with an increased risk of suffering from seizures during the follow-up period. In fact, a PSQI score<5 or an ESS score<10 resulted significantly associated with the absence of seizure recurrence (p<0.004 and p<0.001, respectively). Increasing age had a significantly protective effect in the risk of seizure relapse.
Our findings show that reduced sleep quality and daytime sleepiness in patients with JME increase the risk of seizure occurrence in spite of an appropriate pharmacological treatment. This negative effect seems to be more relevant in younger patients. Sleep disorders and their specific correction should be taken into consideration for the management of patients with JME.
本研究旨在使用睡眠问卷调查青少年肌阵挛性癫痫(JME)患者睡眠障碍的存在情况。此外,我们试图评估睡眠质量的改变是否会影响JME的临床表现。
纳入62例接受左乙拉西坦治疗的JME患者。收集人口统计学和临床变量。此外,所有患者均提交匹兹堡睡眠质量指数(PSQI)和爱泼华嗜睡量表(ESS),以分别评估过去一个月的睡眠质量和白天嗜睡情况。所有患者随访6个月,并分为两组:无癫痫发作组(第1组)和癫痫复发组(第2组)。PSQI和ESS评分分别合成为二元变量<5/≥5和<10/≥10。进行综合分析以评估睡眠质量和白天嗜睡对随访期间癫痫发作风险的独立影响。
过去一个月睡眠质量下降和白天嗜睡均与随访期间癫痫发作风险增加相关。事实上,PSQI评分<5或ESS评分<10与无癫痫复发显著相关(分别为p<0.004和p<0.001)。年龄增加对癫痫复发风险有显著的保护作用。
我们的研究结果表明,尽管进行了适当的药物治疗,但JME患者睡眠质量下降和白天嗜睡会增加癫痫发作的风险。这种负面影响在年轻患者中似乎更为明显。在JME患者的管理中应考虑睡眠障碍及其具体纠正措施。